Arena vs Vivus in a head to head competition of would you rather.
Investing is often filled with tough choices and opportunity costs. This game segment from The Motley Fool's Where The Money Is poses a hypothetical question:
Would you rather buy VIVUS (Nasdaq: VVUS) or buy Arena (NASDAQ: ARNA)?
Healthcare analysts David Williamson and Michael Douglass continue their game of "would you rather" by discussing two competing obesity drug makers struggling with lackluster sales. Watch and find out which stock David chooses and his arguments for it.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
